It is not approved for prescription, dispensing, or supply to the general public in the UK
Retatrutide is currently being studied for its potential role in: Supporting healthy weight management Improving blood glucose regulation Enhancing insulin sensitivity Reducing appetite and food intake Increasing feelings of fullness (satiety) Increasing energy expenditure Supporting fat metabolism and fat oxidation Improving overall metabolic health Investigating obesity, type 2 diabetes, and obesity-related conditions Clinical trials have demonstrated substantial improvements in body weight and metabolic markers, with ongoing Phase 3 studies continuing to evaluate its long-term safety and effectiveness
Semaglutide (Wegovy/Ozempic) activates only GLP-1 and produces roughly 15% weight loss at 68 weeks
A systematic review and meta-analysis of randomised controlled trials evaluating weight reduction diets, with or without exercise, reported an 18% reduction in all-cause mortality over a median follow up of two years in adults with obesity
M., Tolhurst, G., Rogers, G
Estefania Valencia-Rincn, et al
,aspect=ignore)
